Hypothyroidism During Immune Checkpoint Inhibitor Therapy That Is Not Responsive to Thyroxin Substitution. A Peripheral T4-T3 Conversion Block?

por Verelst, Faro, Beyens, Michiel, Vandenbroucke, Elke, Forceville, Kathleen, Twickler, Theodorus Bartholomeus
Publicado 2021

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

por Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick
Publicado 2015